Bulletin

Pfizer's Sutent effective in pancreatic cancer

ValBrickates Kennedy

BOSTON (MarketWatch) -- Pfizer Inc.
PFE, +2.62%
said Thursday that a Phase III clinical trial of its oncology drug Sutent showed the product was effective in slowing the progression of a certain type of pancreatic cancer known as pancreatic neuroendocrine tumors. Sutent is currently approved to treat advanced kidney cancer and a type of gastrointestinal cancer known as GIST.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.